GlassScriptPhysician profile
Margaret H Terhune
NPI 1720008246
$13,427.65
in general payments reported to CMS, 2019-2025
37 companies · $1,245 in 2025
The $1,245 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,207 · 2020: $1,252 · 2021: $2,246 · 2022: $2,044 · 2023: $2,441 · 2024: $1,994 · 2025: $1,245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,679.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,679.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,680.36 | 2019-2025 | Skyrizi, Rinvoq, Botox |
| Janssen Biotech, INC. | $1,160.38 | 2019-2025 | Tremfya |
| Ucb, INC. | $1,152.78 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $1,029.82 | 2019-2025 | |
| Amgen INC. | $849.24 | 2020-2025 | Otezla, Enbrel, Otezla |
| Sun Pharmaceutical Industries INC. | $748.88 | 2019-2025 | Winlevi, Absorica Ld, Ilumya |
| Leo Pharma INC. | $680.42 | 2019-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $636.53 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $584.25 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $520.10 | 2019-2024 | |
| Arcutis Biotherapeutics, INC. | $503.22 | 2023-2025 | Zoryve |
| Incyte Corporation | $417.31 | 2022-2025 | Opzelura |
| Galderma Laboratories, L.P. | $396.86 | 2019-2025 | Nemluvio |
| Lilly USA, LLC | $371.42 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Dermavant Sciences, INC. | $368.19 | 2022-2024 | Vtama |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $221.15 | 2020-2021 | |
| Allergan, INC. | $134.22 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $114.26 | 2019-2021 | |
| Almirall LLC | $99.42 | 2019-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $87.74 | 2019-2020 | |
| Epi Health, LLC | $83.36 | 2019-2021 | |
| Encore Dermatology INC. | $83.19 | 2019-2020 | |
| Verrica Pharmaceuticals INC. | $73.51 | 2023-2024 | Ycanth |
| Mallinckrodt Hospital Products INC. | $52.02 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $51.18 | 2022-2025 | Sotyktu |
| Mission Pharmacal Company | $46.33 | 2019-2021 | |
| Celgene Corporation | $46.22 | 2019 | |
| Aclaris Therapeutics, INC. | $45.73 | 2019 | |
| Promius Pharma LLC | $41.88 | 2019 | |
| Journey Medical Corporation | $28.74 | 2022 | |
| Organon LLC | $22.43 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.44 | 2022 | |
| Merck Sharp & Dohme LLC | $19.87 | 2022 | |
| Genentech USA, INC. | $17.74 | 2019 | |
| Medtronic Vascular, INC. | $15.36 | 2020 | |
| Medtronic, INC. | $14.03 | 2021 | |
| Hill Dermaceuticals, INC. | $9.07 | 2025 | Tolak |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Terhune listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.